BACKGROUND: Repeated measurements of spirometry and fractional exhaled nitric oxide (FENO) are recommended as part of the management of childhood asthma, but the evidence base for such recommendations is small. We tested the hypothesis that reducing spirometric indices or increasing FENO will predict poor future asthma outcomes.
Asthma is a common condition affecting 1 million children in the United Kingdom 1 and 6 million in the United States. 2 Guidelines recommend that objective markers of respiratory function (eg, FEV 1 ) and airway inflammation (eg, fractional exhaled nitric oxide [FENO] ) may be used in conjunction with symptoms to guide asthma preventive treatment in children. These recommendations differ between guidelines, however, and none gives clinicians advice how to interpret changes in spirometry when values fall within the normal range, yet FEV 1 (the most commonly used spirometric index) is usually within normal limits. 3 One guideline recommends that lung function should be "monitored and recorded" only in children >12 years of age. 4 Two guidelines recommend that FEV 1 may be useful for monitoring of asthma for children aged between ages 5 and 7 years. 5, 6 A fourth guideline 7 recommends that lung function should be measured 3 to 6 months after treatment is started and "periodically" thereafter, and that %FEV 1 <60% identifies a patient at risk for future asthma exacerbations. A fifth guideline 8 recommends that lung function should be measured every 1 to 2 years (more frequently when symptoms are poorly controlled) and suggests that treatment might be stepped up if %FEV 1 is <80% or <60%. Some guidelines suggest that a 20% drop in FEV 1 relative to personal best identifies an individual at risk for future asthma exacerbations. 5, 7 Although FENO is recommended by the US Food and Drug Administration for monitoring asthma, 9 there is no consensus on how results should be interpreted; one international guideline states that a change in FENO of 10 ppb or 20% may be clinically relevant. 10 To understand the relationship between change in spirometry and FENO and asthma outcomes, we obtained individual patient data (IPD) from seven FENO randomized controlled trials (RCTs) in which details of spirometry, FENO, asthma control, and the occurrence of asthma exacerbations were collected longitudinally. [11] [12] [13] [14] [15] [16] [17] Our primary hypothesis was that falling spirometric indices (with %FEV 1 as the primary index) and/or rising FENO between randomization and 3-month follow-up will be associated with increased risk for asthma being uncontrolled and for an asthma exacerbation between 3-and 6-month follow-up. The secondary hypothesis was that, at baseline, low spirometric indices and high FENO will be associated with increased risk for asthma being uncontrolled and for an asthma exacerbation between baseline and 3-month follow-up.
Methods

Study Design
Authors of published RCTs in which measurements of FENO were used to guide asthma treatment in children 18 were invited to provide anonymized data for IPD. 19 The outcomes were asthma exacerbation (defined as a prescription of prednisolone during the follow-up period and derived using data provided by study authors) and poor asthma control (defined by per trial protocol by symptom score, and including FEV 1 cutoff values in some trials 11, 12, 16 but not including an asthma exacerbation). e-Appendix 1 provides definitions of being uncontrolled. For all RCTs, prescribing oral corticosteroids for asthma exacerbations was at the discretion of the attending doctor. The explanatory variables between baseline and 3-month follow-up were absolute change and %change in FENO and absolute change in percentage of predicted (%) spirometry; the analysis of change in % spirometry and % change in FENO included the corresponding baseline measurement. The relationship between outcomes and the following explanatory variables at baseline were sought: FENO and %FEV 1 , %FEV 1 /FVC, forced expiratory flow at 25% to 75% of FVC (%FEF ), and %FVC. Figure 1 shows which physiological measurements (and changes) were linked to later asthma outcomes in this study. Additional covariates collected at baseline and included in the models were: age, sex, height, weight, ethnicity, trial arm, dose of inhaled corticosteroid (ICS, as daily budesonide equivalent dose), prescribed long-acting beta agonist (LABA) or not, prescribed leukotriene receptor agonist (LTRA) or not, asthma control, and treatment compliance. For each follow up visit, the following variables were collected: FENO, FEV 1 , height, dose of ICS, asthma control, and asthma exacerbation since the previous visit. The focus of this study was follow-up at 3 and 6 months because these are typically used in asthma clinics; for trials in which there was no 3-or 6-month assessment, the assessment closest to these time points was used. In all but two studies, 14, 15 absolute spirometry data were available and expressed as percentage of predicted to the Global Lung Initiative (GLI) standard 20 ; where absolute data were not available, the % predicted value provided by the local team was used for analysis. Although % FEV 1 was the primary spirometric index of interest, %FEV 1 /FVC, %FEF , and %FVC were also considered to determine which index had the greatest precision for future outcomes. For completeness, FEV 1 was also expressed as z score and centile (standardized to the GLI standard 20 ). Additionally, as a sensitivity analysis, %FEV 1 was derived using National Asthma Education and Prevention Program (NHANES) III standard 21 to determine whether any relationship between %FEV 1 and later outcome was dependent on the standard used. BMI was derived and International Obesity Task Force weight categories created. 22 In each trial, FENO was measured in accordance with the 2005 guideline. 23 Ethical approval was obtained for each individual study but was not required for the IPD.
Individual Patient Data Analysis
Demographic and baseline characteristics were obtained for each study. A one-stage IPD meta-analysis was undertaken using the melogit command in STATA with study included as a random effect. All models were adjusted for the baseline variables of age, sex, LABA, LTRA, asthma control, ICS dose, arm of trial and, where relevant, baseline FENO or baseline FEV 1 . A one-stage approach was used rather than a two-stage approach become some of the studies had low event counts (few asthma exacerbations), and adoption of onestage in this instance is recommended by Burke et al. 24 Sensitivity analyses considered separately outcomes for individuals in FENO intervention and standard care arms of the trials and also excluded data from trials in which %FEV 1 was used to guide treatment decisions. 11, 12, 16 STATA, version 14, was used for analysis.
Results
Study Subjects
Data from seven pediatric RCTs were analyzed (Table 1) 11-17
; data from an eighth RCT could not be obtained. 25 Details of population inclusion and exclusion criteria are presented in e-Appendix 1. The IPD included data on 1,112 participants. In two studies, 14, 17 spirometry was measured at baseline and at 12 months only, and change in %FEV 1 between baseline and 3 months could not be calculated. There was a predominance of male participants (58%) and mean (SD) age was 12.6 (3.1) years ( (18) . Details of mean FEV 1 z scores and centile are presented in e- Table 1 . The Pearson correlation coefficient between FENO and %FEV 1 at baseline was -0.184 (n ¼ 1,025, P < .001) and between % change in FENO (baseline to 3 months) and change in %FEV 1 (baseline to 3 months) was -0.127 (n ¼ 759, P < 001). Overall, 7% of participants had an asthma exacerbation during the first 3 months and 12% in the second 3 months, whereas 27% were uncontrolled at baseline, 25% at 3 months, and 23% at 6 months, (Table 3 ). An asthma exacerbation occurred between baseline and 3 months in 47 (7%) of the 718 participants with controlled symptoms at baseline and in 27 (12%) of 230 with uncontrolled symptoms at baseline.
Relationship Between Change in Spirometry and Percentage Change in FENO Between Baseline and 3 Months and Outcomes Between 3 and 6 Months
Between baseline and 3 months, the mean (SD) change in %FEV 1 was -0.17 (10.4), the median absolute change in FENO was 0.6 ppb (IQR, -7.9, 12.2), and the median % change in FENO was 3.7% (IQR, -30.4, 66.7). A fall in % FEV 1 was related to increased odds of an asthma exacerbation over the following 3 months (eg, a reduction of 10% FEV 1 between baseline and 3 months was associated with increased OR for future exacerbation between 3 and 6 months of 1. a Although %FEV 1 was the primary spirometric index, the following were also considered: %FEV 1 /FVC, %FEF , and %FVC. FENO ¼ fractional exhaled nitric oxide.
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c FEV 1 alone were used in the treatment algorithm for both arms of the RCT but were not used to define being uncontrolled in this study. Table 2 . A 50% increase in FENO between baseline and 3 months was associated with 11% increased odds of asthma being uncontrolled at 6 months (95%, 0-16; P ¼ .014) but not odds of an exacerbation between 3 and 6 months (Table 4) . When both change in %FEV 1 and %change in FENO were considered in the same model, the OR for asthma being uncontrolled remained significant for FENO (P ¼ .036) but not for %FEV 1 (P ¼ .061). Neither change in %FEV 1 /FVC or %FEF (e- Table 2 ) nor absolute change in FENO (Table 4) were associated with outcomes. The associations between change in %FEV 1 and % change in FENO did not achieve significance when each trial arm was considered separately (e- Table 3 ). When the RCTs in which %FEV 1 was used to guide treatment were excluded, there was an association between rising FENO and future asthma exacerbation (P ¼ .029), but associations between change in FEV 1 and outcomes were not significant (e- Table 4 ). Among the subset of RCTs in which FEV 1 z score and centile values could be derived, falling z scores were associated with increased odds for both asthma exacerbations and being uncontrolled and falling centile score with being uncontrolled (e- Table 5 ). The results seen with change in % FEV 1 using the GLI standard were also seen when the NHANES III standard was used (e- Table 6 ).
Relationship Between Baseline FENO and Spirometric Indices and Outcomes at 3Months
Percentage of predicted FEV 1 /FVC at baseline (but no other spirometric index) was related to the odds of asthma exacerbation at 3 months during this interval (P ¼ .016; Table 5 ). No index of spirometry at baseline was related to having uncontrolled asthma at 3 months. FENO at baseline was not related to asthma outcomes at 3 months (Table 5 ). e- Table 6 demonstrates that when FEV 1 was standardized to the NHANES III data, reducing %FEV 1 at baseline was associated with increased odds for future asthma exacerbation (P ¼ .033) and a trend for reduced odds for asthma not being controlled in future (P ¼ .055). Baseline FEV 1 z score or centile were not related to outcomes (e- Table 7) .
Discussion
This study sought to understand the relationship between changes in spirometric measurements and FENO and future asthma outcomes. The first finding was that, independent of all factors that might influence treatment decisions, falling %FEV 1 (even within the range of 80% to 120% commonly considered as "normal") was associated with increased odds for future asthma exacerbation and having uncontrolled asthma. A second finding was that an absolute change in FENO (Table 4) did not predict outcomes, and only a large rise in % change in FENO was related to a small increase in the odds for having uncontrolled asthma in the future. We also observed that at baseline, a "one-off" %FEV 1 /FVC ratio (but not %FEV 1 ) was associated with future odds for asthma exacerbation. Together, the results suggest that change in %FEV 1 can be used as part of risk assessment for asthma outcomes. The role of change in FENO is less clear, and future clinical trials could include % change in FENO as part of a treatment algorithm for children with asthma.
The individuals whose data contributed to this study were participating in RCTs, and this could mean that the results are not necessarily generalizable for at least two reasons. First, participants in RCTs often have to fulfill specific eligibility criteria, receive more clinical contact than standard care, and often have better outcomes such Results are from a 1-stage individual patient data analysis. All models adjusted for sex, age, treatment with long-acting beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline, and change in dose of inhaled corticosteroid between baseline and 3 mo. See Table 1 as fewer asthma exacerbations, but these differences are likely to weaken any association between FENO or %FEV 1 and asthma outcomes by narrowing the phenotype of participants and improving outcomes. Second, the participants in our study had treatment guided by FENO (and %FEV 1 in three studies); thus, the predictive variables in our study may have affected the outcome (eg, rising FENO leading to increased ICS resulting in good asthma control). We justify inclusion of data from these trials because, first, FENO and, in all but one study, 14 %FEV 1 , did not differ between trial arms during the RCT; second, if FENO or %FEV 1 did improve asthma outcomes by protocol-driven treatment changes, this would have weakened any association between FENO or %FEV 1 and asthma control or asthma exacerbations. Our inclusion of participants in RCTs may therefore have weakened the associations described; in "real life," change in %FEV 1 and % change in FENO may have greater precision for outcomes than indicated by our results.
There are some limitations to our study. First, the methodologies of the RCTs were different; in particular, three of the RCT [15] [16] [17] intervals between assessments did not include multiples of 3 months. This heterogeneity may have weakened the associations described, assuming that the relationship between FENO and FEV 1 and outcomes changes over time. Different methods were used to assess asthma control; again, this would weaken and not strengthen the associations described between baseline %FEV 1 or %change in FENO and being uncontrolled in future. A second limitation is that the range of %FEV 1 values was relatively narrow and the incidence of asthma exacerbations was relatively low; this could make the relationship between physiological measurement and clinical outcome difficult to detect. Nonetheless, we were still able to observe an association between %FEV 1 and future asthma exacerbations. A third limitation is that we did not have an objective measure of adherence and could not consider how nonadherence may have influenced asthma control and exacerbations; however, this information is not available for most clinicians and thus our study reflects the real world. A fourth limitation is that none of the RCTs included an assessment of short-term variability of pulmonary function, such as PEF variability or bronchodilator response, and we are not able to say how short-term variability in pulmonary function might be related to future asthma outcomes.
The magnitude of the change in OR for an asthma exacerbation or being uncontrolled in future in the context of changing %FEV 1 and FENO were relatively small, and this is partly because we included RCT participants as previously discussed and partly because the model considered many other factors that might predict poor asthma outcomes (eg, current symptom control, treatment level, current %FEV 1 ).
In our sensitivity analyses, we excluded the three studies in which %FEV 1 was used to guide treatment; the results seen in the whole population were no longer significant, and this is most likely explained by lack of power. When we split results by trial arm, the significant associations seen between change in %FEV 1 and %change in FENO for the whole population were also nonsignificant; this is also most likely because of a lack of power in the analysis. Results are from a 1-stage individual patient data analysis. All models adjusted for sex, age, treatment with long-acting beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline, and change in dose of inhaled corticosteroid between baseline and 3 mo. a For %FEV 1 , "per unit" means for each percentage reduction (eg, from 98% to 97% FEV 1 ) and for FENO "per unit" means per part per billion change (eg, from 35 to 36 ppb).
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We are not aware of published studies that relate change in spirometry to future asthma outcomes, but there are several studies in which spirometry on a single occasion has been related to subsequent asthma outcomes in children. One study reported an inverse relationship between reduced %FEV 1 and increased risk for asthma exacerbation in the next 12 months. 26 Two further studies 27, 28 (data from one 27 contributed to the present IPD) reported that reduced FEV 1 /FVC ratio was associated with increased risk for future exacerbation.
The 2015 European Respiratory Society Task Force on Monitoring Asthma in Children 29 stated that "the meaning of significant changes in FENO in a longitudinal setting is still unclear and needs further attention, and that "the use of 'personal best' cut-off points in FENO algorithms requires further investigation." Our study findings suggest that a relatively large rise (50%) in FENO over 3 months (independent of treatment and initial symptoms) may be a useful predictor of having uncontrolled asthma in future but not for asthma exacerbations. Additionally, our results suggest that a single FENO value and absolute change in FENO over time are unlikely to be clinically useful.
In summary, our results suggest that %FEV 1 within the "normal" range over 3-month periods could assist with risk assessment in childhood asthma. These findings now need replicating elsewhere. A fall in %FEV 1 and a rise in FENO should prompt an evaluation of medication adherence, inhaler technique, perception of symptoms, and exposure to either allergens or viral infection. The relationship between changes in FENO measurements and asthma outcomes is less clear and requires further evaluation.
